Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial

Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY Trial

Sodium glucose cotransporter 2 (SGLT2) inhibitors have both glucose-lowering and diuretic effects. We recently reported that the SGLT2 inhibitor dapagliflozin exerts short-term fluid homeostatic action in patients with chronic kidney disease (CKD). However, the long-term effects of SGLT2 inhibitors...

Full description

Bibliographic Details
Main Authors: Kentaro Oka, Takahiro Masuda, Ken Ohara, Marina Miura, Masato Morinari, Kyohei Misawa, Yasuharu Miyazawa, Tetsu Akimoto, Kazuyuki Shimada, Daisuke Nagata
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
SGLT2 inhibition
body fluid homeostasis
vasopressin
copeptin
loop diuretic
renin-angiotensin aldosterone system
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1287066/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1287066/full

Similar Items